Noncovalent Interaction of α2-Antiplasmin with Fibrin(ogen): Localization of α2-Antiplasmin-Binding Sites-Reference-Cited by-同舟云学术

Noncovalent Interaction of α2-Antiplasmin with Fibrin(ogen): Localization of α2-Antiplasmin-Binding Sites

Published:2010-08-17 Issue:35 Volume:49 Page:7643-7651
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Tsurupa Galina¹,Yakovlev Sergiy¹,McKee Patrick²,Medved Leonid¹

Affiliation:

1. Center for Vascular and Inflammatory Diseases and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201

2. Warren Medical Research Center, Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73190

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/bi1010317

Reference47 articles.

1. Plasmin and Matrix Metalloproteinases in Vascular Remodeling

2. Elements of the Fibrinolytic System

3. New insights into the molecular mechanisms of the fibrinolytic system

4. Molecular mechanisms of initiation of fibrinolysis by fibrin

5. Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency *

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrinogen: Structure, abnormalities and laboratory assays;Advances in Clinical Chemistry;2024

2. Citrullination of α2-antiplasmin is unlikely to contribute to enhanced plasmin generation in COVID-19 pathophysiology;Research and Practice in Thrombosis and Haemostasis;2023-08

3. PLCL/PCL Dressings with Platelet Lysate and Growth Factors Embedded in Fibrin for Chronic Wound Regeneration;International Journal of Nanomedicine;2023-02

4. Transglutaminase Activities of Blood Coagulant Factor XIII Are Dependent on the Activation Pathways and on the Substrates;Thrombosis and Haemostasis;2022-12-06

5. Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism;Clinical and Applied Thrombosis/Hemostasis;2022-01